drugset / Trial / NCT02385058

Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population

NCT02385058

Phase 4 Completed 100 enrolled Janssen-Cilag Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of the combination of mebendazole plus quinfamide for the treatment of intestinal helminthiasis and amoebiasis in Mexican population.

Timeline

Start
2005-10
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mebendazole Small molecule 600 mg Oral
Subject Quinfamide Small molecule 200 mg Oral

Indications